Potent and selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor (IC50
= 21 nM). Displays 30-fold selectivity for IRAK4 over IRAK1. Inhibits LPS-induced TNF-α
and IL-6 production in PBMCs in vitro
. Renoprotective and anti-inflammatory in a rodent model of chronic kidney disease.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.
Renoprotective effects of novel interleukin-1 receptor-associated kinase 4 inhibitor AS2444697 through anti-inflammatory action in 5/6 nephrectomized rats.
Kondo et al.
Naunyn Schmiedebergs Arch.Pharmacol., 2014;387:909
Blocking innate immunity to slow the progression of chronic kidney disease.
Schmaderer and Heemann
Naunyn Schmiedebergs Arch.Pharmacol., 2014;387:905